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ABSTRACT: Sampling site, technique and time influence postmortem drug concentrations. In 57 cases we 
studied drug concentration differences as follows: subclavian vein - dissection/clamping vs. blindstick, femoral 
vein - dissection/clamping vs. blindstick, right cardiac chamber and popliteal vein – dissection and clamping 
only. Cases were distributed in group #1 (all cases with both techniques), group #2 (dissection/clamping) and 
group #3 (blindstick). Sampled drugs were diazepam, methadone, morphine, and their metabolites. To assess 
PMR, mean concentrations and ratios were calculated for each group. Time-dependent variations of blood 
concentrations and ratios were also assessed. Results indicate that site, method and time may influence 
postmortem distribution interpretation in different ways. Popliteal blood seems less subject to PMR. In 
conclusion, our study is the first to evaluate concurrently three main aspects of PMR and confirms that the 
popliteal vein may represent a site that is more resistant to the changes seen as a result of PMR. 
 
KEYWORDS: forensic science, forensic toxicology, postmortem redistribution, sampling site, sampling 
technique, blind stick, sissection/clamping, postmortem interval, popliteal blood 
Postmortem redistribution (PMR) refers to the postmortem processes that change the distribution of drugs in 
tissues, resulting in blood concentration variations depending on the site where blood is sampled and the post-
mortem interval elapsed at the time of sampling. This complex phenomenon is still not entirely understood but 
authors generally agree on the involvement of 3 main factors. First, passive drug diffusion from reservoir organs 
(i.e. heart, liver, lungs and proximal gastro-intestinal tract) to adjacent organs and nearby blood vessels may 
occur as a consequence of the non-uniform distribution of drug in body tissues during life as well as the presence 
of unabsorbed substances in the digestive tract, both resulting in concentration gradients. Second, cellular 
acidification and autolysis can lead to accumulation of basic compounds in tissues as well as disruption of the 
protein binding characteristics of substances. Third, basic, lipophilic, highly protein-bound drugs and those with 
a large volume of distribution are more prone to PMR. While almost all drugs exhibit some degree of PMR, it is 
almost impossible to predict the extent to which a substance will redistribute after death (1-9). 
While not strictly redistribution, postmortem degradation of compounds can also lead to changes in drug 
concentration that can often be confused with redistribution, such as the hydrolysis of morphine glucuronides 
after prolonged postmortem periods (10-12) and the conversion of nitrobenzodiazepines by postmortem bacteria 
metabolism (13).  
Sampling from central sites (subclavian vessels and heart) tends to be more affected by redistribution than 
peripheral sites (iliac and femoral vessels) as central blood vessels often show higher postmortem concentrations 
due to their proximity to reservoir organs and thoraco-abdominal viscera, which are more prone to rapid 
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decomposition. Popliteal vessels are also peripheral sites, unexplored so far. We studied popliteal blood 
concentrations of diazepam, methadone and morphine, and showed that sampling from this site results in drug 
concentrations lower than those in cardiac, subclavian and even femoral sampling. This suggests that popliteal 
blood is less prone to PMR, probably because of its distance from the trunk and isolation from many of the 
factors that alter postmortem drug concentrations (14,15)  
The extent to which a drug is prone to postmortem redistribution is usually described by the ratio of the central 
(C) to peripheral (P) concentration of a drug, or C/P ratio (1,2,6,7,16). The greater the ratio, the greater the extent 
of postmortem redistribution; on the contrary, a ratio less than or equal to 1 suggests absence of redistribution. 
However, some authors suggest that the C/P ratio is not always a reliable indicator of postmortem redistribution 
for a particular substance as seen with C/P ratios greater or less than 1 in cases associated with incomplete 
distribution or cardiopulmonary resuscitation attempts, as well as with C/P ratios greater than 1 for drugs that are 
theoretically not subject to redistribution (1,17,18). Hence, the liver to peripheral blood (L/P) ratio has also been 
evaluated as a possible alternative marker of PMR (17-21).  
As mentioned above, differences in drug concentrations in postmortem blood samples taken from different sites 
can also arise from an incomplete distribution of the drug at the time of death, and not exclusively from 
postmortem redistribution; it is therefore important to keep in mind that demonstrating site-to-site differences in 
the blood concentrations of a particular drug does not necessarily prove that the drug undergoes postmortem 
redistribution (16,22,23). 
How blood is sampled may also affect the measurement of drug concentrations. It has been suggested that 
clamping the femoral vessel before sampling may prevent possible contamination from more central sites due to 
the retrograde flow of blood as it can happen with a blind stick sampling. Therefore, femoral sampling done after 
dissection and clamping of the vein is currently considered the method of choice since it prevents the caudal 
flow of blood from more central sources such as iliac vessels and the inferior vena cava (1-3). However, this 
procedure results in added time to the external examination as well as additional incisions, and some medico-
legal offices simply perform a blind stick femoral sample without tying off the femoral vein. There are only few 
references comparing techniques: some authors used dissection and clamping of the vein, others did a blind stick 
method and some did not mention which sampling method they used.  Hargrove et al. concluded that the blind 
stick method of drawing femoral blood, the easiest, least invasive as well as least time-consuming procedure, did 
not have significant redistribution from central sites and was of equivalent quality to a clamped femoral sample 
for selected drugs (benzodiazepines-diazepam and opiates-hydrocodone), for sampling volumes up to 30 ml (24). 
The same authors did not observe significant changes in either clamped or unclamped femoral vein morphine 
concentrations over time either as well as at any period of sampling within the first 24 hours after death in bodies 
kept refrigerated at 4°C (25). With subclavian sampling, there are publications suggesting that the subclavian 
vein should not be considered a strictly central site, but rather an intermediate one (16,26), but we did not find 
any study addressing adequately the issue of subclavian sampling techniques. Consequently, we evaluated the 
sampling method in a recent study and our results showed that diazepam and methadone concentrations were 
lower when drawn from either clamped subclavian or femoral vein whereas subclavian morphine mean 
concentrations tend to be lower when drawn from a clamped subclavian vein, but not for femoral sampling 
(14,27). Hence, we suggested that clamping vessels and isolating them from heart or abdominal blood may result 
in lower concentrations depending on the drug. There was no difference between right and left popliteal samples. 
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Other than sampling site and technique, the postmortem interval appears to be important. From the available 
data, it seems that redistribution mainly occurs in the early postmortem period, as significant increases in 
concentrations by passive diffusion from reservoir organs have been demonstrated during the first postmortem 
hours for many substances (1,28-32). However, cellular autolysis and bacterial metabolism may also result in 
later changes, both in central and peripheral sites (33-36). Conversely, some studies have determined that there is 
little evidence of time dependent variability at either central or peripheral site (5,37). 
In the present study, we sampled a number of drugs from central (heart and subclavian veins) and peripheral 
(femoral and popliteal veins) sites and we evaluated the influence of the site of sampling, the sampling technique 
(for subclavian and femoral sites) as well as the time of sampling, respectively, on the blood drug concentrations 
and ratios.  
We chose drugs more commonly abused in the jurisdiction of the Medico-Legal Institute of the University of 
Liège, Belgium. These were diazepam, methadone and morphine as well as their respective metabolites. 
Concerning their potential for postmortem redistribution, different and sometimes controversial trends are found 
in the literature. Diazepam may not have significant PMR; however, heart/femoral blood mean ratios greater 
than one are found in the literature on relatively large series, suggesting that PMR may explain at least partially 
site-to-site difference in diazepam concentration (38,39). Nordiazepam may not exhibit redistribution according 
to the mean C/P ratios found in the literature whereas oxazepam exhibits some degree of redistribution in one 
study (16,40-42). Methadone is thought to undergo significant redistribution (3,16,39,43-45). Morphine may 
(2,16,39,46,47) or may not (33,37,48) exhibit significant redistribution, whereas many animal models have 
shown that morphine does undergo redistribution (2,31,49,50); furthermore, studies suggested that postmortem 
increases in free morphine concentration could be due, at least partially, to hydrolysis of morphine glucuronides 
rather than postmortem redistribution and an increase in the free/total morphine concentration ratio would be 
seen with increasing hydrolysis (31,50,51). The chemical properties of selected substances may influence PMR: 
diazepam is a lipophilic weak base (pKa 3.4) with a low Vd (0.7-2.6 L/kg), nordiazepam has pKa 3.5 and Vd 
0.5-2.5 L/kg and oxazepam has pKa 1.7 and Vd 0.7-1.6L/kg; methadone is a lipophilic base (pKa 8.6) with a 
larger Vd (4-7 L/kg); morphine is a hydrophilic amphoteric base (pKa 7.9, 9.6), but lipid soluble at physiologic 
pH, with an intermediate Vd (2-5 L/kg) whereas Vd is approximately 0.28 L/kg for morphine glucuronides 
(2,41,47). Moreover, morphine glucuronides can exist in two conformational forms, the folded conformers being 
more lipophilic; certain site-to-site variation could be associated with the ambiguous nature of morphine-
glucuronides (47,52). 
According to some authors, diazepam is stable in blood and tissues (53,54), even with putrefaction (55), unlike 
other benzodiazepines (9,55,56) although this can depend on specimen preservation (56), temperature (56-58) 
and other factors (58); nordiazepam is less stable in postmortem unpreserved blood (53). Methadone was found 
to be stable in postmortem blood (54,59). Concerning the stability of morphine, some authors did not see 
significant changes in morphine concentrations in patient samples and stored blood even when compared with 
admission and postmortem blood, in some cases for days after the sample was drawn (25,47,48,54,60). Other 
studies showed that low pH, increased storage time, temperature and degree of putrefaction resulted in greater 
free morphine generation (10) whereas morphine and its glucuronides were stable in sampled post-mortem blood 
only when stored at -20°C (12,61). 
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Our study has three goals: first, to confirm the influence of sampling site; secondly, to assess the influence of 
sampling method by comparing blind stick with dissection/clamp technique; finally, to evaluate the influence of 
postmortem interval. 
 
Methods 
In this study, we included 57 cases of drugs intoxications referred to our medico-legal office in Liège during a 
2,5-year period, i.e. from November 2012 to April 2015. When possible, a urine drug screen was done to assess 
the presence of the drugs of interest (Drug-Screen®, nal von minden GmbH, Regensburg, Germany). If not, the 
case was selected according to history and medicolegal context.  
Cases were sampled as follows: subclavian blood - dissection/clamp technique (SBD), subclavian blood - 
blindstick technique (SBB), femoral blood - dissection/clamp technique (FBD), femoral blood - blindstick 
technique (FBB), intracardiac blood (ICB) and popliteal blood (PB). 
Thirty cases were sampled with single specimens taken as follows: 
- cardiac blood was drawn in the right atrium after a small chest incision; 
- at subclavian and femoral sites, transcutaneous blind stick sampling was done on the left side of the 
body while a dissection with proximal clamping of the vessel was done on the right; 
- popliteal blood was collected from both sides. 
A second group of 27 cases was sampled twice at the same sites as above, with the first sample always done on 
the left side of the body and the second sample on the right side after a recorded time interval (generally greater 
than 24 h), along with cardiac blood taken in the right atrium for both samples. The same sampling technique 
was used for subclavian and femoral samples in the same case, but we alternated sampling methods from case to 
case.  
Popliteal sampling always required dissection because of its depth in the knee; the popliteal vein was clamped as 
cephalad as possible to prevent any theoretical femoral blood reflux. Compression of the leg was sometimes 
required to obtain an adequate amount of blood for testing.  
Cases were distributed in 3 groups: group #1 (n=57) included all cases, group #2 (n=42) concerned cases with 
dissection/clamping technique at subclavian and femoral sites and group #3 (n=45) those cases with blindstick 
technique at subclavian and femoral sites.  
In order to assess the influence of sampling site and technique on PMR, for each substance and for each group, 
mean concentrations ratios were calculated as follows: [cardiac]/[subclavian], [cardiac]/[femoral], 
[cardiac]/[popliteal], [subclavian]/[femoral], [subclavian]/[popliteal] and [femoral]/[popliteal]. Ratios were also 
compared between groups #2 and #3 to assess the difference between blind stick and vein dissection techniques. 
To evaluate the influence of postmortem interval, two methods were used. The first method, (method 1) studied 
in all cases (n=57) and for each substance, the correlation between the concentration ratios and the corresponding 
estimated postmortem interval. The second method (method 2) studied only in those cases sampled twice (n=27) 
and for each substance, the differences of concentrations and ratios between both samples. To assess the 
contribution of hydrolysis of morphine-glucuronides to free morphine, free morphine/total morphine ratios 
differences were also calculated in cases sampled twice where morphine and both morphine-glucuronides were 
present (n=12).  Postmortem changes as well as elements collected from death scene allowed calculation of the 
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estimated postmortem interval in method 1 while the precise time elapsed between both samples was recorded in 
method 2.  
Mean sampled blood volumes were the following: ICB 7.6 ml (range 1-12 ml); SBD 6.4 ml (range 0.5-16 ml); 
SBB 8.7 ml (range 1-16 ml); FBD 6.3 ml (range 1-12 ml); FBB 6.9 ml (range 1-16 ml); PB 4.5 ml (range 0.5-8 
ml).  
Drugs concentrations were quantified, as follows: diazepam and its metabolites nordiazepam and oxazepam; 
methadone and its metabolite EDDP; morphine and its metabolites morphine-3-glucuronide and morphine-6-
glucuronide.  
Blood samples were collected in sodium fluoride/potassium oxalate (2%) vials and frozen at -20 °C prior to 
analysis done within the first 4 to 6 weeks after sampling. 
Quantitative Analysis 
The quantification of morphine and methadone was performed on an ultra-high pressure liquid chromatograph 
Acquity® coupled to a tandem mass spectrometer Quattro Premier® (Waters, Zellik, Belgium). After solid phase 
extraction of the sample on Oasis MCX® cartridges, the separation was performed on an Acquity HSS T3 
column. The mobile phase consisted in a gradient of ammonium formate (pH 3) and acidified methanol (62).  
Diazepam was analyzed in blood using a high performance liquid chromatography with photodiode array 
detection (Alliance®, Waters, Zellik, Belgium) based on a method described by Gaillard et al. (63). After a 
liquid-liquid extraction using a mixture of diethyl ether, dichlormethane, hexane and n-amyl alcohol, the sample 
was injected on a Symmetry C8 column with phosphate buffer (pH 3.8) and acetonitrile delivered according to a 
gradient  elution as mobile phase. Considering low, intermediate and high concentration, respectively, 
coefficients of variation (CV) were the following: 6.02 %, 4.00 % and 3.22 % for diazepam; 5.88 %, 3.24 % and 
2.60 % for nordiazepam; 6.02 %, 3.88 % and 3.66 % for oxazepam; 3.33 %, 5.08 % and 6.41 % for methadone ; 
8.29 %, 15.33 % and 1.10 % for EDDP; 6.64 %, 4.24 % and 7.10 % for morphine; 5.52 %, 5.23 % and 6.02 % 
for morphine-3-glucuronide; 4.64 %, 6.74 % and 5.57 % for morphine-6-glucuronide.  
A single quantitation of analytes was carried out for each sampling site. Quality and validation of each analysis 
was ensured through two levels of control (one internal, the other commercial) and by the use of a multipoint 
calibration curve (7 points and a blank). 
Statistical Analysis 
Statistical analyses were performed by using SAS software (version 9.3 for windows) and R software. Normality 
of the distributions was checked by using a Shapiro-Wilk test. A logarithmic transformation of concentrations 
was also used to normalize the distributions. Quantitative variables were summarized by the mean, standard 
deviation (SD), median, minimum and maximum. Qualitative variables were summarized by means number (N) 
and percentage (%). 
Mean Concentrations and Mean ratios in All Cases (Group 1) 
In Group #1 (n=57), for each substance, mean concentrations at each site were calculated for all cases and the 
sampling sites were compared with a non-parametric Friedman test. Results were considered as statistically 
significant at 5% level (p< 0.05). For each substance, drug concentrations differences between sites were 
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calculated as follows: ICB – SB, ICB – FB, ICB – PB, SB –FB, SB –FB, and FB – PB. A non-parametric 
Wilcoxon signed-rank test was used to assess a significant concentration difference. For each substance, the 
following ratios were calculated: ICB / SB, ICB / FB, ICB / PB, SB / FB, SB / PB, and FB / PB. A non-
parametric Wilcoxon signed-rank test was also utilized to assess a significant ratio, i.e. a ratio different to 1. 
For the comparison of concentrations at the different sampling sites and for the comparison of mean ratios, a 
Bonferroni’s correction (0.05/6 = 0.0083) was used to consider statistically significant results (p<0.0083). 
 
Mean Concentrations and Mean Ratios in Cases with Dissection/Clamping Technique at Subclavian and 
Femoral Sites (Group 2) 
In Group #2 (n=42), for each substance, mean concentrations at each site were calculated and the sampling sites 
were compared with a non-parametric Friedman test. Results were considered as statistically significant at 5% 
level (p< 0.05). For each substance, drug concentrations differences between sites were calculated as follows: 
ICB – SBD, ICB – FBD, ICB – PB, SBD –FBD, SBD – PB, and FBD – PB. A non-parametric Wilcoxon signed-
rank test was used to assess a significant concentration difference. For each substance, the following ratios were 
calculated: ICB / SBD, ICB / FBD, ICB / PB, SBD / FBD, SBD / PB, and FBD / PB. A non-parametric 
Wilcoxon signed-rank test was also utilized to assess a significant ratio, i.e. a ratio different to 1. For the 
comparison of concentrations at the different sampling sites and for the comparison of mean ratios, a 
Bonferroni’s correction (0.05/6 = 0.0083) was used to consider statistically significant results (p<0.0083). 
 
Mean Concentrations and Mean Ratios in Cases with Transcutaneous Blindstick Technique at Subclavian and 
Femoral Sites (Group 3) 
In Group #3 (n=45), for each substance, mean concentrations at each site were calculated and the sampling sites 
were compared with a non-parametric Friedman test. Results were considered as statistically significant at 5% 
level (p< 0.05). For each substance, drug concentrations differences between sites were calculated as follows: 
ICB – SBB, ICB – FBB, ICB – PB, SBB –FBB, SBB – PB, and FBB – PB A non-parametric Wilcoxon signed-
rank test was used to assess a significant concentration difference. For each substance, the following ratios were 
calculated: ICB / SBB, ICB / FBB, ICB / PB, SBB / FBB, SBB / PB, and FBB / PB. A non-parametric Wilcoxon 
signed-rank test was also utilized to assess a significant ratio, i.e. a ratio different to 1. For the comparison of 
concentrations at the different sampling sites and for the comparison of mean ratios, a Bonferroni’s correction 
(0.05/6 = 0.0083) was used to consider statistically significant results (p<0.0083). 
Influence of Estimated Postmortem Interval on Mean Ratios in All Cases (n=57) (Method 1) 
For each substance, non-parametric Spearman correlation coefficients were calculated to assess the correlation 
between mean ratios and estimated postmortem interval. A negative coefficient showed a decreasing relation 
between the two parameters (when one increased, the other decreased) while a positive coefficient showed an 
increasing relation (when one increased, the other increased too). For assessing the influence of estimated post-
mortem interval, results were considered as statistically significant at 5% level (p< 0.05). 
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Mean Concentrations and Ratios Differences in Cases Sampled Twice (n =27) (Method 2) 
For each substance, mean concentrations at each site and mean ratios calculated for samples 1 and 2 were 
compared by using a non-parametric Wilcoxon signed-rank test. For each substance, non-parametric Spearman 
correlation coefficients were calculated to assess the correlation between mean concentrations and ratios 
differences and the time interval elapsed between samples 1 and 2. A negative coefficient showed a decreasing 
relation between the two parameters (when one increased, the other decreased) while a positive coefficient 
showed an increasing relation (when one increased, the other increased too). For assessing the influence of time 
interval between samples 1 and 2, results were considered as statistically significant at 5% level (p< 0.05). In 
order to assess the possible contribution of hydrolysis of morphine-glucuronides to free morphine between 
samples 1 and 2, free morphine/total morphine ratios differences between samples 1 and 2 were also compared 
by using a non-parametric Wilcoxon signed-rank test.  
 
Results 
Table 1 shows, for all cases, age, sex and average estimated postmortem interval as determined by the protocol 
in use by our office. 
Table 2 shows, for all cases, assayed substances and their metabolites as well as their respective frequencies. 
 
Influence of Sampling Site in All Cases (Group #1) 
Figure 1 (a,b,c), Figure 2 (a,b), and Figure 3 (a,b,c), show mean blood concentrations distribution according to 
sampled drugs in all cases. All concentrations are expressed in microgram per liter of blood (µg/L).  
For morphine (n=49), methadone (n=60) and their respective metabolites, morphine-3-glucuronide (n=47), 
morphine-6-glucuronide (n=39) and EDDP (n=52), mean concentrations tend to decline the further the sampling 
site is from the heart. 
For diazepam (n=24) as well as its metabolites nordiazepam (n=26) and oxazepam (n=14), results show slightly 
higher femoral mean concentrations than central sites concentrations; furthermore subclavian mean 
concentrations are also greater than cardiac site.  
For all sampled drugs, popliteal mean concentrations are lower than other three sites. 
Cardiac and subclavian sites show no significant mean concentration differences for the three compounds and 
their metabolites except for morphine-6-glucuronide (p=0.0011). Cardiac and femoral sites show statistically 
significant mean blood concentrations differences for diazepam (p=0.0063), morphine (p<0.0001) and EDDP 
(p=0.0046) whereas cardiac and popliteal sites mean concentrations are significantly different for morphine 
(p<0.0001), methadone (p<0.0001) and EDDP (p<0.0001). For morphine (p<0.0001), methadone (p<0.0001) 
and EDDP (p=0.0055), subclavian and femoral sites also show significant mean concentration differences while 
all substances show significant mean concentration differences between subclavian and popliteal site (p<0.0001 
for nordiazepam, methadone, EDDP, morphine, and morphine-6-glucuronides; p=0.0046 for diazepam; 
p=0.0004 for morphine-3-glucuronide), except oxazepam (p=0.022). Finally, for all substances, popliteal mean 
concentrations are significantly lower than femoral mean concentrations (p<0.0001 for diazepam, nordiazepam, 
methadone, EDDP, and morphine; p=0.0031 for nordiazepam; p=0.0006 for morphine-3-glucuronide; p=0.0059 
for morphine-6-glucuronide). 
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To assess the occurrence of postmortem redistribution, for each substance, the following average ratios of 
concentrations were obtained: ICB/SB, ICB/FB, ICB/PB, SB/FB, SB/PB and FB/PB as shown in Table 3. 
For diazepam and its metabolites, ICB/SB mean ratios are less than or equal to 1 whereas ICB/FB and SB/FB 
mean ratios are consistently less than the corresponding ICB/PB and SB/PB ratios. FB/PB ratios are also 
consistently greater than the more usual central (cardiac/subclavian) / peripheral (femoral/popliteal) ratios. 
For methadone and EDDP, we see that ICB/SB mean ratios are slightly greater than or close to 1 for methadone 
but show a greater difference for EDDP. For both compounds, ICB/FB and SB/FB mean ratios are consistently 
less than the ICB/PB and SB/PB ratios, respectively. FB/PB ratios are consistently lower than the more usual 
central (cardiac/subclavian) / peripheral (femoral/popliteal) ratios, except for EDDP SB/FB less than FB/PB. 
For morphine and morphine-glucuronides, results show that morphine ICB/SB mean ratio is greater than 1 
whereas an opposite trend is seen for both morphine-glucuronides. ICB/FB and SB/FB mean ratios are 
consistently less than the corresponding ICB/PB and SB/PB ratios. FB/PB ratios are also consistently lower than 
the more usual central (cardiac/subclavian) / peripheral (femoral/popliteal) ratios for morphine and morphine-6-
glucuronide, with the exception of morphine-6-glucuronide FB/PB greater than ICB/FB. Conversely, for 
morphine-3-glucuronide, FB/PB mean ratio is consistently greater than (cardiac/subclavian)/(femoral/popliteal) 
mean ratios. 
ICB/SB mean ratios are not statistically significant, i.e. different from 1, for any substances. ICB/FB mean ratios 
are not statistically significant, i.e. different from 1, for any substances except for diazepam (p=0081), EDDP 
(p=0.008), and morphine (p<0.0001). ICB/PB mean ratios are statistically greater than 1, methadone (p<0.0001), 
EDDP (p<0.0001), and morphine (p<0.0001), but are not statistically significant, i.e. different from 1, for 
diazepam, oxazepam, and both morphine glucuronides. SB/FB means ratios are statistically greater than 1, for 
methadone (p<0.0001), EDDP (p=0.0006), and morphine (p<0.001), but show no signification, i.e. different 
from 1, for the other sampled substances. SB/PB mean ratios are statistically greater than 1 for all substances, 
except for oxazepam (p=0.022). FB/PB mean ratios are statistically greater than 1 for all substances and their 
metabolites. 
 
Influence of Subclavian and Femoral Sampling Technique on Mean Concentrations and Ratios (Group #2 and 
#3) 
Figure 4 (a,a’,b,b’,c,c’), Figure 5 (a,a’,b,b’), and Figure 6 (a,a’,b,b’,c,c’), show mean blood concentrations 
distribution according to sampling technique used at subclavian and femoral sites. All concentrations are 
expressed in microgram per liter of blood (µg/L).  
For diazepam (group #2 n=20; group #3 n =18), nordiazepam (group #2 n=22; group #3 n =20), and oxazepam 
(group #2 n=12; group #3 n =10), mean concentrations tend to decline the further the sampling site is from the 
heart with dissection/clamping technique at subclavian and femoral sites (group#2), except for oxazepam with 
mean ICB lower than SBD. With blind stick sampling at the same sites (group #3), we see an opposite trend as 
mean concentrations tend to decrease the closer to the heart is the site, except for oxazepam mean ICB greater 
than SBB. However, for diazepam, nordiazepam and oxazepam, popliteal mean concentrations are lower than 
other sites for both techniques used at subclavian and femoral sites.  
For methadone (group #2 n=38; group #3 n=46) and EDDP (group #2 n=34; group #3 n=42), mean 
concentrations tend to decline the further the sampling site is from central sites with dissection/clamping method 
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(group#2) as well as with the blindstick technique (group #3). Moreover, popliteal mean concentrations are still 
lower than other sites for both groups. 
For morphine (group #2 n=33; group #3 n=33), mean concentrations tend to decline the further the sampling site 
is from central sites with both sampling techniques used at subclavian and femoral sites; however, subclavian 
and femoral concentrations tend to be closer to cardiac concentrations with dissection/clamping method. For 
morphine-3-glucuronide (group #2 n=33; group #3 n=31) and morphine-6-glucuronide  (group #2 n=29; group 
#3 n=25), with dissection/clamping technique (group#2), we see a different trend as femoral concentrations are 
greater than subclavian and close to cardiac concentrations; with blind stick sampling (group #3), cardiac and 
subclavian mean concentrations are obviously greater than femoral site whereas subclavian concentration tends 
also to be higher than cardiac site. Though, popliteal mean concentrations are lower than other sites for both 
groups for morphine and its metabolites, as observed for the other sampled drugs. 
In group #2, ICB and SBD show no significant mean concentration differences for all compounds and 
metabolites. ICB and FBD show statistically significant mean blood concentrations differences for morphine 
(p=0.003) and EDDP (p=0.0056) while cardiac and popliteal sites mean concentrations are significantly different 
for morphine (p<0.0001), methadone (p=0.0003) and EDDP (p<0.0001). For morphine (p=0.0012) and 
methadone (p<0.0001), SBD and FBD sites also show significant mean concentration differences whereas 
significant mean concentration differences between SBD and PB are found for nordiazepam (p<0.0001), 
morphine (p<0.0001), methadone (p<0.0001) and EDDP (p<0.0001). Finally, for morphine (p<0.0001), 
methadone (p<0.0001) and EDDP (p<0.0001), PB mean concentrations are significantly lower than FBD mean 
concentrations.  
In group #3, ICB and SBB sites show no significant mean concentration differences for the three parent drugs 
and their metabolites. ICB and FBB sites show statistically significant mean concentrations differences for 
diazepam (p=0.0028), morphine (p<0.0001) and EDDP (p=0.0037). For methadone (p<0.0001), EDDP 
(p<0.0001), and morphine (p<0.0001), cardiac and popliteal sites show significant mean concentration 
differences; so do SBB and FBB for methadone (p<0.0001), EDDP (p=0.0001), morphine (p<0.0001), and 
morphine-6-glucuronide (p<0.0001). SBB and PB show significant mean concentrations differences for 
methadone (p<0.0001), EDDP (p=0.0001), morphine (p<0.0001) and metabolites (p<=0.0001) as well as for 
nordiazepam (p=0.0014). Except for morphine-6-glucuronide (p=0.05) and oxazepam (p=0.084), PB mean 
concentrations are significantly lower than FBB mean concentrations for all sampled drugs.  
To assess the occurrence of postmortem redistribution according to sampling technique used, for each substance, 
the following average ratios of concentrations were obtained as shown in Table 4: ICB/SBD, ICB/FBD, ICB/PB, 
SBD/FBD, SBD/PB, and FBD/PB in group #2; ICB/SBB, ICB/FBB, ICB/PB, SBB/FBB, SBB/PB, and FBB/PB 
in group #3.  
For diazepam and its metabolites, ICB/SBD mean ratios are equal to or slightly greater than ICB/SBB ratios 
whereas ICB/FBD ratios are consistently greater than ICB/FBB; SBD/FBD mean ratios are also greater than 
SBB/FBB for the three sampled substances. Conversely, diazepam and nordiazepam show SBD/PB mean ratios 
slightly less than SBB/PB ratios while oxazepam SBD/PB mean ratio is greater than SBB/PB. FBD/PB mean 
ratios are consistently less than FBB/PB ratios for all three drugs. 
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With methadone, we see only slight differences between ICB/SBD and ICB/SBB mean ratios as well as between 
ICB/FBD and ICB/FBB; the same trend is found when comparing SBD/FBD and SBB/FBB. However, SBD/PB 
and FBD/PB mean ratios are less than SBB/PB and FBB/PB mean ratios, respectively. For EDDP, 
cardiac/subclavian and cardiac/femoral mean ratios are consistently greater with dissection/clamping technique 
than with blindstick sampling at subclavian and femoral sites whereas subclavian/femoral mean ratios are lower 
with dissection/clamping method than with the other sampling technique. Accordingly, SBD/PB and FBD/PB 
mean ratios are less than SBB/PB and FBB/PB mean ratios, respectively. 
For morphine and morphine-glucuronides, ICB/SBD mean ratios are greater than ICB/SBB while an opposite 
trend is seen with ICB/FBD mean ratios less than ICB/FBB. SBD/FBD and SBD/PB are less than SBB/FBB and 
SBB/PB, respectively. However, FBD/PB appears equal to FBB/PB for morphine, whereas FBD/FB is greater 
than FBB/PB for both morphine-glucuronides.  
In group #2, ICB/SBD mean ratios are not statistically significant, i.e. different from 1, for any substances. 
ICB/FBD mean ratios are not statistically significant, i.e. different from 1, for any substances except for EDDP 
(p=0.0016) and morphine (p=0.0006). ICB/PB mean ratios are statistically greater than 1 for methadone 
(p<0.0001), EDDP (p<0.0001), and morphine (p<0.0001). SBD/FBD means ratios are statistically greater than 1 
for methadone (p<0.0001) and morphine (p=0.0002). SBD/PB mean ratios are statistically greater than 1 for 
nordiazepam (p<0.0001), methadone (p<0.0001), EDDP (p<0.0001), and morphine (p<0.0001) whereas 
diazepam mean ratio is really close to significance (p=0.0083). FBD/PB mean ratios are statistically greater than 
1 for methadone (p<0.0001), EDDP (p<0.0001), and morphine (p<0.0001).  
In group #3, ICB/SBB mean ratios are not statistically significant, i.e. different from 1, for any substances. 
ICB/FBB mean ratios are statistically significant, i.e. different from 1, for diazepam (p=0.0090), EDDP 
(p=0.0007) and morphine (p<0.0001). ICB/PB mean ratios are statistically greater than 1 for methadone 
(p<0.0001), EDDP (p<0.0001), morphine (p<0.0001), and morphine-6-glucuronide (p=0.0066). SBB/FBB mean 
ratios are statistically greater than 1 for methadone (p<0.0001), EDDP (p=0.0001), morphine (p<0.0001), and 
morphine-6-glucuronide (p<0.0001). SBB/PB mean ratios are statistically greater than 1 for nordiazepam 
(p=0.0010), methadone (<0.0001), EDDP (<0.0001), morphine (p<0.0001), morphine-3-glucuronide (p<0.0001), 
and morphine-6-glucuronide (p<0.0001). FBB/PB mean ratios are statistically greater than 1 for all substances 
and their metabolites, except oxazepam (p=0.027) and morphine-6-glucuronide (p=0.022). 
 
Influence of Estimated Postmortem Interval on Mean Ratios (Method 1) 
In all cases (n=57), for each substance, in order to assess the influence of postmortem interval on mean ratios, 
the correlations between ratios of concentrations obtained and the estimated postmortem interval were calculated 
as shown in Table 5.  
For diazepam, there is a significant correlation between postmortem interval and SB/FB (r = -0.49, p = 0.015) as 
well as FB/PB (r = 0.61, p = 0.0017). For nordiazepam, a significant correlation is found between postmortem 
interval and SB/PB (r = 0.42, p = 0.034) but also FB/PB (r = 0.58, p = 0.0019). There is no significant 
correlation observed for oxazepam. 
For methadone, there is only one significant correlation observed between postmortem interval and FB/PB (r = 
0.56, p < 0.0001) whereas no significant correlation is seen with EDDP. 
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For morphine, there is no significant correlation observed whereas significant correlations are seen for morphine-
glucuronides. For morphine-3-glucuronide, we see a significant correlation between the postmortem interval and 
the following ratios: ICB/PB (r = 0.38, p = 0.0079), SB/PB (r = 0.37, p = 0.011) and FB/PB (r = 0.39, p = 
0.0068). For morphine-6-glucuronide, the following ratios are correlated with the postmortem interval: ICB/PB 
(r = 0.43, p = 0.0066) and SB/PB (r = 0.40, p = 0.011). 
 
Comparison of Mean Concentrations and Ratios in Cases Sampled Twice (Method 2) 
In order to compare mean concentrations and ratios between samples 1 and 2 in cases sampled twice (n=27), for 
each substance and at each site, mean concentrations and mean ratios differences were calculated according to 
the mean time interval elapsed between both samples as shown in Figure 7-9 (a,b,c) and Table 6, respectively. 
Concentrations differences are expressed in microgram per liter of blood (µg/L). 
Moreover, in order to assess the possible contribution of hydrolysis of morphine-glucuronides to free morphine, 
only in those cases where parent drug and both metabolites were present (n=12), free morphine/total morphine 
(i.e. free morphine + morphine-3-glucuronide + morphine-6-glucuronide) ratios differences between samples 1 
and 2 were also calculated as shown in Table 7.  
Concerning concentrations differences, for diazepam (n = 5, mean time interval 27.4 h +/-9.9), nordiazepam (n = 
5, mean time interval 27.4 h +/- 9.9), and oxazepam (n = 3, mean time interval 30.7 h +/-12.42), we see different 
trends. ICB mean concentrations tend to decrease with time except for oxazepam, whereas SB mean 
concentration also appears to decrease for diazepam and oxazepam but shows increase with time for 
nordiazepam. For all three substances, FB shows mean concentrations increase between sample 1 and 2 while 
PB mean concentration consistently decreases with time. Methadone (n=18, mean time interval 27.2 h +/-13.8) 
and EDDP (n=14, mean time interval 27.0 h +/-15.4), both show ICB mean concentrations decrease, SB mean 
concentrations increase as well as PB mean concentrations increase between samples 1 and 2, whereas FB mean 
concentration tends to increase with time for methadone but shows an opposite trend for EDDP. For morphine 
(n=16, mean time interval 29.0 h +/-14.3) and morphine-glucuronides (morphine-3-glucuronide n=15, mean time 
interval 29.6 h +/-14.6 – morphine-6-glucuronide n=12, mean time interval 30.9 h +/-16.2)  we see that ICB 
mean concentrations decrease with time while both SB and FB mean concentrations show increase between 
samples 1 and 2. PB mean concentrations show marked decrease with time for morphine-glucuronides but 
morphine mean concentration shows only slight increase between the two samples. However, those results are 
only statistically significant for the following mean concentrations differences: SB2-SB1 for EDDP (p=0.0040), 
SB2-SB1 for methadone (p=0.0090), SB2 – SB1 for morphine (p=0.0042), PB2 – PB1 for morphine-3-
glucuronide (p<0.0001) and PB2 – PB1 for morphine-6-glucuronide (p=0.0005).  
When it comes to the possible contribution of morphine-glucuronides hydrolysis to free morphine, in 12 cases 
where morphine and both morphine-glucuronides were samples twice, we see that free/total morphine mean 
ratios show increases for all sampling sites; increases are statistically significant for all sampling sites except 
ICB. Furthermore, free morphine/total morphine ratios increases are also more important the further the 
sampling site is from the heart.  
There are differences in the concentration ratios of diazepam and its metabolites. ICB/SB, ICB/FB, ICB/PB and 
SB/FB mean ratios tend to decrease with time for diazepam and nordiazepam whereas oxazepam shows decrease 
for ICB/FB and SB/FB mean ratios but an increase for ICB/SB and ICB/PB. SB/PB mean ratio difference with 
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time is nearly null for diazepam while it shows increase for nordiazepam and decrease for oxazepam, 
respectively, between samples 1 and 2. FB/PB mean ratio shows increase with time for all three compounds. 
Methadone and EDDP both show ICB/SB, ICB/FB and ICB/PB mean ratios decreases between samples 1 and 2 
while SB/FB and SB/PB mean ratios tend to increase with time for both substances. For FB/PB mean ratio 
difference, we see an increase with time for methadone but an opposite trend for EDDP. When it comes to 
morphine and morphine-glucuronides mean ratios differences, results show that all mean ratios increase with 
time for morphine. For both morphine-glucuronides, ICB/SB and ICB/FB mean ratios tend to decrease between 
samples 1 and 2 whereas ICB/PB mean ratio shows increase for morphine-3-glucuronide but decrease with time 
for morphine-6-glucuronide; besides, both metabolites show increase with time for other mean ratios, i.e. SB/FB, 
SB/PB and FB/PB.  As for the study of mean concentrations differences, only a limited number of results are 
statistically significant, i.e. SB2/PB2 - SB1/PB1 for methadone (p=0.039), ICB2/SB2 - ICB1/SB1 for EDDP 
(p=0.030), SB2/PB2 - SB1/PB1 and FB2/PB2 - FB1/PB1 for morphine-3-glucuronide (p=0.0020 and p=0.0042, 
respectively), as well as SB2/PB2 - SB1/PB1 and FB2/PB2 - FB1/PB1 for morphine-6-glucuronide (p=0.0005 
and p=0.0021, respectively).   
Correlation coefficients also were calculated to assess the correlations between mean concentrations as well as 
ratios differences and the time interval elapsed between samples 1 and 2; correlations were not statistically 
significant for any substance, except for oxazepam mean concentrations differences at femoral (r=0.99, 
p=0.0026) and popliteal (r= -0.1, p<0.0001) sites as well as for methadone mean ICB/PB differences (r=0.57, 
p=0.014) and oxazepam mean ICB/FB (r=1.0, p<0.0001), ICB/PB (r=1.0, p<0.0001) and FB/PB differences 
(r=1.0, p<0.0001).      
 
Discussion 
 
Influence of Sampling Site 
Evaluation of the sampling site in all cases shows that mean concentrations tend to decline the further it is from 
the heart for methadone and morphine, as well as their respective metabolites. Conversely, diazepam and its 
metabolites show slightly higher femoral blood concentrations compared to cardiac and subclavian sites, as well 
as mean subclavian concentrations also greater than cardiac blood; results suggest that these benzodiazepines 
may undergo degradation in central sites. In general, nitrobenzodiazepines (e.g. clonazepam, nitrazepam, 
flunitrazepam) are among the most unstable owing to bacterial reduction of the nitro group whereas 
benzodiazepines without the N-oxide or nitro groups appear to display greater stability in biological specimens 
(13,56). However, Skopp et al. showed that the concentration of 13 benzodiazepines including diazepam and 
nordiazepam significantly decreased in unpreserved blood (58). Hence, the more intense degradation of 
diazepam and metabolites in central sites may explain our findings. For all sampled drugs, popliteal mean 
concentrations are lower than the other three sites.  
PMR average ratios find different trends. First, ICB/SB mean ratios are close to 1 and have no significant 
differences for any of the sampled compounds, indicating that the subclavian vein is a central site. Secondly, 
ICB/FB and SB/FB mean ratios are consistently less than the corresponding ICB/PB and SB/PB for all targeted 
substances, suggesting than PMR is more apparent when comparing central sites with the popliteal versus the 
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femoral site. Third, FB/PB mean ratios are statistically greater than 1 for all drugs and their metabolites, 
suggesting that popliteal blood may be less prone to PMR, which we reported previously (15). 
 
Effect of Sampling Technique 
Diazepam and metabolites mean concentrations tend to decline the further from the heart with the 
dissection/clamp method; the opposite of the trend is seen with a blind stick, as mean concentrations tend to 
decrease the closer the sample is to the heart. This suggests that dissection/clamping at subclavian and femoral 
sites may result in isolation from both central degradation and PMR processes, respectively. Therefore, sampling 
techniques allow us nuancing the aforementioned discussion about degradation of diazepam and metabolites in 
central sites since postmortem processes of redistribution may also probably interfere. As a consequence, the 
blind stick method may account for drawing central blood mixed from both degradation and redistribution 
processes, with degradation of drugs being probably more intense than redistribution, resulting in an increase of 
mean concentrations the further from the heart. On the contrary, dissection/clamp technique of subclavian and 
femoral vessels may isolate blood from both central processes and their relative importance, resulting in an 
opposite trend with mean concentrations declining the further from the heart. Another hypothesis could be the 
blood contamination with surrounding tissues at the site of blind stick sampling, but probably to a lesser extent 
as diazepam and metabolites exhibit a low volume of distribution even if they are lipophilic. Moreover, the 
popliteal mean concentrations are lower than other three sites for all sampling methods. Study of mean ratios 
confirms these trends for the three sampled substances. In addition, diazepam and nordiazepam show SBD/PB 
mean ratios slightly less than SBB/PB while FBD/PB mean ratios are consistently less than FBB/PB ratios for all 
three drugs, suggesting that subclavian and femoral blood mean concentrations are closer to popliteal blood 
when isolated from central processes; FBD/PB mean ratios greater than 1 for all three compounds may also 
indicate that popliteal blood is more isolated from PMR even than femoral blood sampled from a clamped 
vessel.  
For methadone and EDDP, with both methods used at subclavian and femoral sites, mean concentrations tend to 
decline the further the sampling site is from the heart. For methadone, when compared to cardiac or popliteal 
mean concentrations, subclavian and femoral mean concentrations do not show obvious differences attributable 
to sampling technique. For EDDP, with the dissection/clamp method, subclavian and femoral mean 
concentrations tend to be proportionally lower than intracardiac blood when compared to a blind stick. Popliteal 
mean concentrations are lower than the other three sites for both techniques. Mean ratios correspond with these 
results. For methadone and EDDP, SBD/PB and FBD/PB mean ratios are less than corresponding SBB/PB and 
FBB/PB mean ratios, respectively. Hence, results suggest that both the subclavian and femoral 
dissection/clamping techniques result in isolation from central PMR processes even if this is more evident in 
central sites with EDDP than with the parent drug. Moreover, FBD/PB mean ratios are significantly greater than 
1 for both compounds, indicating that popliteal blood is still more isolated from PMR processes than femoral 
clamped vessel. 
For morphine, for both techniques at subclavian and femoral sites, we still see mean concentrations declining the 
further the sampling site is from the central blood; however, subclavian and femoral concentrations tend to be 
closer to cardiac concentrations with the dissection/clamp method. This may account for the greater stability of 
morphine further away from central compartments. For both glucuronide metabolites, we see a different trend as 
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femoral concentrations are greater than subclavian and close to cardiac concentrations with dissection/clamping 
method; with blind stick sampling, cardiac and subclavian mean concentrations are greater than those at the 
femoral site, whereas subclavian concentrations tend also to be higher than those from the heart. Hence, for 
morphine-glucuronides, the dissection/clamp method may result in isolation from central PMR processes, even 
though this is more marked at the subclavian than at the femoral site. Popliteal mean concentrations are lower 
than all other sampling methods for morphine and its metabolites, as seen for the other drugs. However, 
morphine ICB/SBD mean ratio is greater than ICB/SBB, different from the trend seen with mean concentrations, 
whereas morphine-glucuronides ICB/SBD mean ratios are greater than ICB/SBB, which is compatible with 
mean concentrations found according to sampling method. As suggested by mean concentrations, for morphine 
and metabolites, an opposite trend is seen with ICB/FBD mean ratios less than ICB/FBB; furthermore, 
SBD/FBD and SBD/PB are less than SBB/FBB and SBB/PB, respectively. For morphine, results suggest 
isolation from PMR processes at central sites whereas isolation from another mechanism such as greater 
instability of the drug in contact with central blood may account for the trend found at femoral site. Moreover, 
FBD/PB appears equal to FBB/PB for morphine, whereas FBD/PB is greater than FBB/PB for both morphine-
glucuronides, suggesting than morphine is less sampling technique-dependent at peripheral sites than its 
glucuronides. Our findings concerning morphine also remind us that PMR has always to be assessed by 
comparison of ratios in addition to mean concentrations. 
 
Influence of Sampling Time  
The first method calculated the correlation between ratios and corresponding estimated postmortem interval in 
all cases. For diazepam, there is a significant negative correlation between postmortem interval and SB/FB but a 
positive correlation with FB/PB, indicating that SB/FB decreases whereas FB/PB increases with time, which is 
compatible with central degradation and peripheral redistribution with time, respectively. For nordiazepam, a 
significant positive correlation is found between postmortem interval and SB/PB but also FB/PB, which is still 
compatible with redistribution of the compound with time. There was no significant correlation observed for 
oxazepam. For methadone, there is only one significant correlation observed between postmortem interval and 
FB/PB, indicating that mean ratio increases with postmortem interval, whereas no significant correlation is seen 
with EDDP; this suggests redistribution of methadone increases with time at the femoral site.  For morphine, 
there is no significant correlation observed whereas significant correlations are seen for morphine-glucuronides: 
morphine-3-glucuronide shows a significant positive correlation between the postmortem interval and ICB/PB, 
SB/PB as well as FB/PB; morphine-6-glucuronide ICB/PB and SB/PB ratios are also correlated with the 
postmortem interval. Hence, the first method suggests that PMR may also correlate with longer postmortem 
interval, and not only in the early postmortem interval as reported by many studies; popliteal blood 
concentrations are also reliably lower than subclavian and femoral blood.  
The second method concerned the evaluation of concentrations differences at the same site as well as ratios 
differences in cases sampled twice.  
There are different trends for postmortem concentration differences between diazepam and its metabolites: ICB 
mean concentrations tend to decrease with time except for oxazepam; SB mean concentrations also appear to 
decrease for diazepam and oxazepam but show an opposite trend for nordiazepam; for all three substances, FB 
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shows mean concentrations increase whereas PB mean concentrations consistently decrease with time. There 
may be degradation of benzodiazepines in central sites depending on the drug, whereas the FB increase may 
result from redistribution process rather than degradation; conversely, PB decrease may be the consequence of 
degradation rather than redistribution. Concerning ratio differences, for diazepam and its metabolites, different 
results are seen according to the substance considered. ICB/SB, ICB/FB, ICB/PB and SB/FB mean ratios tend to 
decrease with time for diazepam and nordiazepam whereas oxazepam also shows decrease for ICB/FB and 
SB/FB mean ratios but an increase for ICB/SB and ICB/PB. SB/PB mean ratio difference with time is nearly null 
for diazepam while it increases for nordiazepam and decreases for oxazepam, respectively. FB/PB mean ratio 
shows increase with time for the three compounds. These results are in accordance with the concentrations 
differences but also allow clarifying their relative differences from site to site, suggesting there is less 
redistribution at the popliteal site as mean ratio differences are greater with PB. 
Methadone and EDDP show ICB mean concentration decrease; SB and PB mean concentrations increase with 
time, whereas FB mean concentration tends to increase for methadone but shows an opposite trend for EDDP. 
Results suggest further redistribution of methadone from surroundings tissues into blood at subclavian, femoral 
and popliteal sites with time, whereas subsequent redistribution of methadone into cardiac tissue and/or 
degradation in cardiac blood may explain methadone decrease with time in ICB; the same trend is found for 
EDDP except at femoral site where subsequent redistribution into surrounding tissues and/or degradation may 
also occur. Accordingly, methadone and EDDP both show ICB/SB, ICB/FB and ICB/PB mean ratios decrease 
while SB/FB and SB/PB mean ratios tend to increase with time for both substances. For FB/PB mean ratio 
difference, we see an increase with time for methadone but an opposite trend for EDDP. The results suggest 
cardiac mean concentrations decrease with concomitant increase in the other sites considered as well as 
simultaneous mean concentrations increase in subclavian and peripheral sites, but to a lesser extent into 
peripheral sites, especially the popliteal site for methadone.  
For morphine and morphine-glucuronides, ICB mean concentrations decrease with time while both SB and FB 
mean concentrations show increases. PB mean concentrations show a marked decrease with time for morphine-
glucuronides but morphine mean concentration shows only a slight increase. Consequently, the ICB decrease 
may be explained by central degradation of morphine and morphine-glucuronides whereas redistribution may 
account for mean concentrations increases in SB and FB. In PB, morphine-glucuronides hydrolysis is not the 
only phenomenon occurring as free morphine showed only slight increase with time compared to the significant 
decrease in concentration of morphine-glucuronides. Hence, redistribution of morphine glucuronides into 
surrounding tissues may also account for their decrease with time as both glucuronides may be more lipophilic or 
tissue degradation allows the passive diffusion from the intravascular compartment into the surrounding tissues. 
Concerning mean ratio differences, results show that all mean ratios increased with time for morphine; however, 
the increase is greater with PB than with FB, suggesting that PB is less affected by the postmortem interval as 
also suggested by FB/PB increase with time. For both morphine-glucuronides, ICB/SB and ICB/FB mean ratios 
tend to decrease with time whereas ICB/PB mean ratio shows increase for morphine-3-glucuronide but decrease 
with time for morphine-6-glucuronide; both metabolites show increase with time for SB/FB, SB/PB and FB/PB. 
Hence, the results for morphine-glucuronides suggest cardiac mean concentrations decrease with concomitant 
increase in the other sites considered (except for morphine-3-glucuronide showing ICB/PB increase) as well as 
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simultaneous mean concentrations increase in subclavian and femoral sites, whereas concentrations 
proportionally decrease in popliteal blood, suggesting different mechanism as discussed before.  
Finally, to assess if the changes in the free morphine concentration between samples could be due to the 
hydrolysis of morphine glucuronides rather than postmortem redistribution, free morphine/total morphine ratios 
differences were calculated. We see that there are increases in the free/total morphine ratio at each site, 
statistically significant for all sites except ICB. However, the role of hydrolysis is unclear as the changes in 
free/total morphine ratios are only partially responsible for the changes seen in morphine with time at the same 
site. Therefore, although hydrolysis of morphine-glucuronides does probably occur and may have a role in the 
differing concentrations of free morphine and morphine-glucuronides, other factors also may influence how 
morphine and morphine-glucuronides specifically redistribute in the postmortem environment, i.e. pH changes 
modifying the equilibrium of the drug in tissue compartments and passive diffusion of the drugs down a 
concentration gradient from area of high concentration to areas of low free concentration, in other words, from 
tissue to blood or from blood to tissue.  
    
In conclusion, our study is the first to evaluate concurrently three aspects of PMR of three selected drugs and 
their metabolites concomitantly sampled at 4 sampling sites, among which the popliteal site unexplored so far by 
other authors. Concerning sampling site, for all substances, popliteal blood mean concentrations are significantly 
lower than those found in femoral blood, a site commonly used for peripheral sampling, indicating that popliteal 
blood is probably less prone to PMR due to its greater distance from the trunk. Sampling method also appears to 
have an effect on subclavian and femoral mean concentrations depending on the substance considered, since 
dissection/clamp technique may isolate blood from central processes; however, mean concentrations still suggest 
that popliteal site is more isolated from PMR processes as femoral/popliteal mean ratios are greater than one 
even with the dissection/clamp femoral sampling technique. Finally, estimated postmortem interval as well as 
time interval between samples in the same case show influence on mean concentrations and mean ratios of 
sampled substances, depending again on the drug considered, but generally indicating that redistribution 
processes are progressive with time; however, PB seems less subject to redistribution with time compared to 
other sites, including femoral site. Hence, our results suggest that PMR is an ongoing phenomenon in central as 
well as in peripheral compartments, but also that popliteal blood seems more resistant to it. 
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TABLE 1-Sex, age and estimated postmortem interval. 
 N Mean +/- SD Min-Max 
Sex    
Male 46   
Female 11   
Age (y) 57 39.4 +/- 9.8 22.7-58.2 
Postmortem interval (h) 57 31.1 +/- 26.2 5.0-145.0 
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TABLE 2—Target substances in all cases.  
 
N 
Diazepam 24 
Nordiazepam 26 
Oxazepam 14 
Methadone 60 
EDDP 52 
Morphine 49 
Morphine-3-glucuronide  47 
Morphine-6-glucuronide 39 
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TABLE 3—Mean concentrations ratios in all cases. 
Substance Ratios N Mean +/- SD Min Median Max Wilcoxon p-
value 
Diazepam ICB/SB 24 0.86 +/-0.28 0.45 0.90 1.41 0.034 
 ICB/FB  0.79 +/-0.34 0.21 0.83 1.46 0.0081* 
 ICB/PB  1.00 +/-0.29 0.46 0.98 1.58 0.72 
 SB/FB  0.93 +/-0.34 0.46 0.85 2.04 0.13 
 SB/PB  1.22 +/-0.31 0.73 1.24 2.02 0.00015 
 FB/PB  1.45 +/-0.75 0.72 1.30 4.35 <0.0001* 
       
 
Nordiazepam ICB/SB 26 0.92 +/-0.27 0.22 0.95 1.44 0.14 
 ICB/FB  0.91 +/-0.31 0.65 1.17 1.81 0.20 
 ICB/PB  1.16 +/-0.30 0.51 1.50 6.24 0.017 
 SB/FB  0.99 +/-0.23 0.38 0.86 1.93 0.68 
 SB/PB  1.36 +/-0.54 0.78 1.26 3.48 <0.0001* 
 FB/PB  1.43 +/-0.66 0.81 1.23 3.64 <0.0001* 
       
 
Oxazepam ICB/SB 14 1.01 +/-0.35 0.27 0.96 1.62 0.95 
 ICB/FB  0.88 +/-0.33 0.41  0.86 1.65 0.14 
 ICB/PB  1.38 +/-0.70 0.76 1.19 3.33 0.068 
 SB/FB  0.96 +/-0.43 0.38 0.86 1.93 0.41 
 SB/PB  1.52 +/-0.98 0.83 1.16 4.39 0.022 
 FB/PB  1.68 +/-0.94 0.83 1.42 3.88 0.0031* 
Methadone ICB/SB 60 1.08 +/-0.83 0.28 0.91 6.15 0.53 
 ICB/FB  1.49 +/-1.25 0.33 1.09 7.37 0.015 
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 ICB/PB  1.91 +/-1.46 0.47 1.51 8.67 <0.0001* 
 SB/FB  1.39 +/-0.66 0.48 1.30 5.49 <0.0001* 
 SB/PB  1.80 +/-0.78 0.89 1.64 5.72 <0.0001* 
 FB/PB  1.36 +/-0.47 0.69 1.21 3.54 <0.0001* 
       
 
EDDP ICB/SB 52 1.25 +/-0.84 0.26 0.95 4.46 0.55 
 ICB/FB  1.69 +/-1.76 0.09 1.19 11.26 0.0008* 
 ICB/PB  2.58 +/-3.42 0.36 1.64 23.78 <0.0001* 
 SB/FB  1.30 +/-0.68 0.36 1.24 4.82 0.0006* 
 SB/PB  2.03 +/-1.76 0.66 1.71 12.50 <0.0001* 
 FB/PB  1.62 +/-0.93 0.78 1.36 6.50 <0.0001* 
Morphine ICB/SB 49 1.35 +/-1.09 0.23 1.03 6.72 0.093 
 ICB/FB  1.90 +/-1.24 0.18  1.57 5.73 <0.0001* 
 ICB/PB  2.60 +/-2.05 0.73 1.94 9.33 <0.0001* 
 SB/FB  1.52 +/-0.72 0.35 1.31 4.09 <0.0001* 
 SB/PB  2.05 +/-1.18 0.65 1.65 7.47 <0.0001* 
 FB/PB  1.49 +/-1.01 0.65 1.20 6.13 0.0061* 
        
Morphine-3-G ICB/SB 47 0.92 +/-0.54 0.15 0.80 2.86 0.13 
 ICB/FB  1.10 +/-0.96 0.05 0.81 3.91 0.43 
 ICB/PB  1.44 +/-1.35 0.21 0.84 7.33 0.36 
 SB/FB  1.20 +/-0.69 0.13 1.07 4.07 0.14 
 SB/PB  1.56 +/-1.03 0.40 1.22 5.73 <0.0001* 
 FB/PB  1.72 +/-2.42 0.59 1.16 17.20 0.002* 
        
Morphine-6-G ICB/SB 39 0.88 +/-0.68 0.11 0.76 3.38 0.0084 
 ICB/FB  1.71 +/-3.33 0.07 0.88 20.50 0.84 
 ICB/PB  2.10 +/-3.51 0.11 1.07 17.57 0.17 
 SB/FB  1.91 +/-2.91 0.13 1.19 17.09 0.012 
 SB/PB  2.48 +/-4.92 0.50 1.43 31.33 <0.0001* 
 FB/PB  1.83 +/-2.66 0.38 1.17 13.82 0.0014* 
 
 
 
 
TABLE 4—Mean concentrations ratios according to sampling techniques at subclavian and femoral sites. 
Substance Ratios N Mean +/- SD Min Median Max Wilcoxon p-
value 
Diazepam ICB/SBD 
ICB/SBB 
20 
18 
0.90 +/-0.30 
0.84 +/-0.32 
0.45 
0.34 
0.89 
0.90 
1.35 
1.46 
0.18 
0.030 
 ICB/FBD 
ICB/FBB 
20 
18 
0.96 +/-0.40 
0.73 +/-0.36 
0.42 
0.12 
0.91 
0.74 
2.07 
1.34 
0.35 
0.0048* 
 ICB/PB (#2) 20 1.02 +/-0.30 0.45 0.99 1.54 0.93 
 ICB/PB (#3) 18 1.04 +/-0.36 0.48 1.04 1.72 0.77 
 SBD/FBD 
SBB/FBB 
20 
18 
1.10 +/-0.36 
0.86 +/-0.35 
0.61 
0.35 
1.10 
0.80 
2.04 
1.47 
0.32 
0.13 
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 SBD/PB 
SBB/PB 
20 
18 
1.18 +/-0.26 
1.35 +/-0.61 
0.80 
0.73 
1.20 
1.19 
1.68 
3.19 
0.0083 
0.016 
 
 
FBD/PB 
FBB/PB 
20 
18 
1.13 +/-0.31 
1.95 +/-1.93 
0.61 
0.91 
1.06 
1.39 
1.93 
9.21 
0.097 
0.0004* 
        
Nordiazepam ICB/SBD 
ICB/SBB 
22 
20 
0.95 +/-0.26 
0.95 +/-0.29 
0.22 
0.54 
0.93 
0.95 
1.40 
1.47 
0.35 
0.44 
 ICB/FBD 
ICB/FBB 
22 
20 
1.06 +/-0.40 
0.87 +/-0.32 
0.21 
0.33 
1.05 
0.95 
2.05 
1.25 
0.54 
0.13 
 ICB/PB (#2) 22 1.17 +/-0.35 0.64 1.16 2.22 0.036 
 ICB/PB (#3) 20 1.20 +/-0.33 0.66 1.22 1.81 0.014 
 SBD/FBD 
SBB/FBB 
22 
20 
1.11 +/-0.25 
0.94 +/-0.31 
0.77 
0.45 
1.12 
0.87 
1.62 
1.58 
0.066 
0.33 
 SBD/PB 
SBB/PB 
22 
20 
1.32 +/-0.55 
1.36 +/-0.54 
0.89 
0.78 
1.19 
1.23 
3.48 
3.19 
<0.0001* 
0.0010* 
 
 
FBD/PB 
FBB/PB 
22 
20 
1.23 +/-0.59 
1.64 +/-1.11 
0.70 
0.99 
1.07 
1.22 
3.64 
5.52 
0.013 
<0.0001* 
        
Oxazepam ICB/SBD 
ICB/SBB 
12 
10 
1.08 +/-0.35 
1.03 +/-0.36 
0.27 
0.63 
1.10 
1.06 
1.55 
1.68 
0.42 
0.85 
 ICB/FBD 
ICB/FBB 
12 
10 
3.43 +/-8.38 
1.24 +/-1.58 
0.52 
0.41 
0.96 
0.80 
30.00 
5.70 
0.97 
0.13 
 ICB/PB (#2) 12 3.68 +/-8.30 0.76 1.25 30.00 0.042 
 ICB/PB (#3) 10 1.31 +/-0.49 0.76 1.23 2.04 0.19 
 SBD/FBD 
SBB/FBB 
12 
10 
3.67 +/-9.24 
1.23 +/-1.48 
0.38 
0.50 
1.05 
0.70 
33.00 
5.40 
0.70 
0.19 
 SBD/PB 
SBB/PB 
12 
10 
3.94 +/-9.17 
1.39 +/-0.64 
0.63 
0.73 
1.16 
1.18 
33.00 
2.71 
0.052 
0.16 
 
 
FBD/PB 
FBB/PB 
12 
10 
1.41 +/-0.83 
1.65 +/-0.96 
0.70 
0.36 
1.13 
1.53 
3.88 
3.82 
0.054 
0.027 
Methadone ICB/SBD 
ICB/SBB 
38 
46 
1.05 +/-0.57 
1.08 +/-0.91 
0.36 
0.23 
0.97 
0.88 
2.59 
6.15 
0.91 
0.43 
 ICB/FBD 
ICB/FBB 
38 
46 
1.57 +/-1.20 
1.50 +/-1.36 
0.33 
0.43 
1.19 
1.03 
5.81 
7.37 
0.018 
0.081 
 ICB/PB (#2) 38 1.86 +/-1.27 0.54 1.49 5.77 <0.0001* 
 ICB/PB (#3) 46 1.97 +/-1.62 0.47 1.45 8.67 <0.0001* 
 SBD/FBD 
SBB/FBB 
38 
46 
1.47 +/-0.64 
1.45 +/-0.93 
0.66 
0.48 
1.36 
1.26 
4.07 
6.98 
<0.0001* 
<0.0001* 
 SBD/PB 
SBB/PB 
38 
46 
1.75 +/-0.63 
1.93 +/-1.10 
0.89 
0.96 
1.65 
1.69 
4.04 
7.69 
<0.0001* 
<0.0001* 
 
 
FBD/PB 
FBB/PB 
38 
46 
1.25 +/-0.31 
1.41 +/-0.51 
0.87 
0.69 
1.18 
1.27 
2.27 
3.54 
<0.0001* 
<0.0001* 
       
 
EDDP ICB/SBD 
ICB/SBB 
34 
42 
1.47 +/-1.10 
1.23 +/-0.83 
0.63 
0.26 
1.09 
1.01 
5.63 
4.23 
0.043 
0.66 
 ICB/FBD 
ICB/FBB 
34 
42 
2.27 +/-3.65 
1.74 +/-1.55 
0.27 
0.09 
1.25 
1.29 
21.40 
7.64 
0.0016* 
0.007* 
 ICB/PB (#2) 34 3.12 +/-4.61 0.63 1.63 26.75 <0.0001* 
 ICB/PB (#3) 42 2.77 +/-3.47 0.36 1.70 21.40 <0.0001* 
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 SBD/FBD 
SBB/FBB 
34 
42 
1.32 +/-0.73 
1.48 +/-1.06 
0.39 
0.36 
1.22 
1.26 
3.80 
6.87 
0.013 
0.0001* 
 SBD/PB 
SBB/PB 
34 
42 
1.82 +/-0.91 
2.56 +/-3.58 
0.66 
0.88 
1.61 
1.72 
4.75 
23.00 
<0.0001* 
<0.0001* 
 
 
FBD/PB 
FBB/PB 
34 
42 
1.57 +/-0.83 
1.65 +/-1.17 
0.78 
0.79 
1.37 
1.34 
5.00 
8.00 
<0.0001* 
<0.0001* 
Morphine ICB/SBD 
ICB/SBB 
33 
33 
1.40 +/-1.14 
1.26 +/-0.81 
0.50 
0.23 
1.11 
1.06 
6.72 
4.53 
0.10 
0.21 
 ICB/FBD 
ICB/FBB 
33 
33 
1.76 +/-1.21 
1.97 +/-1.36 
0.44 
0.18 
1.34 
1.57 
5.60 
7.17 
0.0006* 
<0.0001* 
 ICB/PB (#2) 33 2.37 +/-1.82 0.72 1.94 9.33 <0.0001* 
 ICB/PB (#3) 33 2.57 +/-1.99 0.86 1.60 8.50 <0.0001* 
 SBD/FBD 
SBB/FBB 
33 
33 
1.37 +/-0.74 
1.60 +/-0.58 
0.35 
0.76 
1.19 
1.47 
4.09 
3.05 
0.0002* 
<0.0001* 
 SBD/PB 
SBB/PB 
33 
33 
1.84 +/-1.18 
2.09 +/-0.93 
0.65 
0.76 
1.55 
1.83 
7.47 
4.67 
<0.0001* 
<0.0001* 
 
 
FBD/PB 
FBB/PB 
33 
33 
1.44 +/-0.88 
1.43 +/-0.92 
0.95 
0.63 
1.24 
1.20 
6.13 
4.86 
<0.0001* 
<0.0001* 
        
Morphine-3-G ICB/SBD 
ICB/SBB 
33 
31 
1.07 +/-0.79 
0.97 +/-0.56 
0.20 
0.10 
0.80 
0.83 
3.56 
2.52 
0.61 
0.43 
 ICB/FBD 
ICB/FBB 
33 
31 
1.16 +/-1.12 
1.29 +/-1.01 
0.05 
0.24 
0.85 
0.84 
4.65 
3.87 
0.35 
0.57 
 ICB/PB (#2) 33 1.45 +/-1.55 0.21 0.81 8.25 0.38 
 ICB/PB (#3) 31 1.74 +/-1.45 0.21 1.10 6.60 0.056 
 SBD/FBD 
SBB/FBB 
33 
31 
1.09 +/-0.61 
1.39 +/-0.84 
0.13 
0.39 
1.09 
1.16 
2.74 
4.07 
0.69 
0.064 
 SBD/PB 
SBB/PB 
33 
31 
1.35 +/-0.76 
1.86 +/-1.23 
0.40 
0.64 
1.17 
1.39 
3.78 
5.73 
0.023 
<0.0001* 
 
 
FBD/PB 
FBB/PB 
33 
31 
1.80 +/-2.84 
1.47 +/-0.81 
0.50 
0.66 
1.13 
1.36 
17.20 
4.60 
0.018 
0.0001* 
        
Morphine-6-G ICB/SBD 
ICB/SBB 
29 
25 
1.11 +/-1.15 
0.91 +/-0.64 
0.11 
0.09 
0.80 
0.76 
5.13 
2.74 
0.15 
0.14 
 ICB/FBD 
ICB/FBB 
29 
25 
1.21 +/-1.48 
2.35 +/-4.01 
0.07 
0.33 
0.70 
1.18 
6.81 
20.50 
0.41 
0.12 
 ICB/PB (#2) 29 1.86 +/-3.58 0.11 0.91 19.25 0.53 
 ICB/PB (#3) 25 2.74 +/-3.88 0.17 1.42 17.57 0.0066* 
 SBD/FBD 
SBB/FBB 
29 
25 
1.05 +/-0.61 
2.72 +/-3.49 
0.13 
0.63 
0.91 
1.75 
3.00 
17.09 
0.84 
<0.0001* 
 SBD/PB 
SBB/PB 
29 
25 
1.32 +/-0.67 
3.48 +/-6.01 
0.47 
0.63 
1.27 
1.92 
3.75 
31.33 
0.015 
<0.0001* 
 
 
FBD/PB 
FBB/PB 
29 
25 
2.08 +/-3.09 
1.29 +/-0.52 
0.47 
0.38 
1.17 
1.28 
17.20 
2.43 
0.019 
0.022 
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TABLE 5—Correlations between estimated postmortem interval and ratios in all cases. 
Substance Ratios N Mean PMI (h) +/-
SD 
Correlation Spearman p-
value 
Diazepam ICB/SB 24 30.88 +/-19.12 -0.43  0.84 
 ICB/FB   -0.35 0.090 
 ICB/PB   0.053 0.891 
 SB/FB   -0.49 0.015* 
 SB/PB   0.17 0.42 
 FB/PB   0.61 0.0017* 
     
 
Nordiazepam ICB/SB 26 29.76 +/-18.77 -0.19  0.35 
 ICB/FB   -0.33 0.098 
 ICB/PB   0.23 0.26 
 SB/FB   -0.33 0.097 
 SB/PB   0.42 0.034* 
 FB/PB   0.58 0.0019* 
     
 
Oxazepam ICB/SB 14 35.94 +/-21.33 0.18  0.53 
 ICB/FB   -0.0042 0.89 
 ICB/PB   0.30 0.30 
 SB/FB   -0.33 0.25 
 SB/PB   0.028 0.92 
 FB/PB   0.34 0.24 
Methadone ICB/SB 60 39.03 +/-33.09 0.020  0.88 
 ICB/FB   -0.15 0.26 
 ICB/PB   0.089 0.50 
 SB/FB   -0.24 0.060 
 SB/PB   0.16 0.22 
 FB/PB   0.56 <0.0001* 
     
 
EDDP ICB/SB 52 34.13 +/-23.71 -0.15  0.30 
 ICB/FB   -0.21 0.13 
 ICB/PB   -0.14 0.32 
 SB/FB   -0.11 0.45 
 SB/PB   -0.11 0.43 
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 FB/PB   0.00051 0.99 
Morphine ICB/SB 49 38.92 +/-28.87 0.24 0.10 
 ICB/FB   0.20 0.16 
 ICB/PB   0.20 0.17 
 SB/FB   0.052 0.72 
 SB/PB   0.12 0.41 
 FB/PB   -0.029 0.85 
      
Morphine-3-G ICB/SB 47 35.91 +/-25.26 0.23  0.12 
 ICB/FB   0.18 0.24 
 ICB/PB   0.38 0.0079* 
 SB/FB   0.17 0.26 
 SB/PB   0.37 0.011* 
 FB/PB   0.39 0.0068* 
     
 
Morphine-6-G ICB/SB 39 37.51 +/-26.74 0.25  0.12 
 ICB/FB   0.23 0.15 
 ICB/PB   0.43 0.0066* 
 SB/FB   0.13 0.43 
 SB/PB   0.40 0.011* 
 FB/PB   0.29 0.076 
 
 
 
 
 
TABLE 6—Mean ratios differences between samples in cases sampled twice. 
Substance Ratios difference N Mean +/- 
SD 
Mean time 
interval (h) 
+/-SD 
Min Median Max Wilcoxon p-
value 
Diazepam ICB 2/SB 2 – ICB 1/SB 1 5 -0.15+/-0.19 27.4+/-9.8 -0.43 -0.08 0.07 0.13 
 ICB 2/FB 2 – ICB 1/FB 1  -0.49+/-0.28  -0.81 -0.51 -0.20 0.063 
 ICB 2/PB 2 – ICB 1/PB 1  -0.18+/-0.09  -0.28 -0.20 -0.05 0.063 
 SB 2/FB 2 – SB 1/FB 1  -0.50+/-0.47  -1.24 -0.44 0.01 0.13 
 SB 2/PB 2 – SB 1/PB 1  -0.01+/-0.32  -0.36 -0.08 0.48 1.0 
 FB 2/PB 2 – FB 1/PB 1  0.62+/-0.40  -0.02 0.79 0.95 0.13 
        
 
Nordiazepam ICB 2/SB 2 – ICB 1/SB 1 5 -0.36+/-0.25 27.4+/-9.8 -0.68 -0.42 -0.04 0.063 
 ICB 2/FB 2 – ICB 1/FB 1  -0.42+/-0.34  -0.84 -0.52 0.08 0.13 
 ICB 2/PB 2 – ICB 1/PB 1 5 -0.16+/-0.24  -0.56 -0.11 0.01 0.31 
 SB 2/FB 2 – SB 1/FB 1  -0.07+/-0.44  -0.50 -0.21 0.61 0.81 
 SB 2/PB 2 – SB 1/PB 1  0.67+/-0.80  0.07 0.46 2.01 0.63 
 FB 2/PB 2 – FB 1/PB 1  0.84+/-0.95  -0.21 0.77 2.38 0.13 
        
 
Oxazepam ICB 2/SB 2 – ICB 1/SB 1 3 0.19+/-0.89 30.6+/-12.4 -0.44 -0.21 1.21 1.0 
 ICB 2/FB 2 – ICB 1/FB 1  -0.24+/-0.25  -0.44 -0.32 0.04 0.50 
Au
th
or
 M
an
us
cr
ip
t
29 
 
This article is protected by copyright. All rights reserved 
 ICB 2/PB 2 – ICB 1/PB 1  0.35+/-0.93  -0.23 -0.15 1.42 1.0 
 SB 2/FB 2 – SB 1/FB 1  -0.61+/-0.82  -1.55 -0.26 -0.03 0.25 
 SB 2/PB 2 – SB 1/PB 1  -0.32+/-0.89  -1.32 0.01 0.35 1.0 
 FB 2/PB 2 – FB 1/PB 1  1.15+/-1.11  0.43 0.60 2.43 0.25 
Methadone ICB 2/SB 2 – ICB 1/SB 1 18 -0.19+/-0.98 27.2+/-13.8 -3.73 -0.02 0.81 0.87 
 ICB 2/FB 2 – ICB 1/FB 1  -0.14+/-1.06  -3.64 -0.04 1.36 0.58 
 ICB 2/PB 2 – ICB 1/PB 1  -0.11+/-1.53  -4.39 0.14 1.76 0.44 
 SB 2/FB 2 – SB 1/FB 1  0.03+/-0.41  -0.57 -0.04 1.02 0.97 
 SB 2/PB 2 – SB 1/PB 1  0.25+/-1.03  -2.72 0.27 2.95 0.039* 
 FB 2/PB 2 – FB 1/PB 1  0.17+/-0.91  -2.85 0.16 1.34 0.099 
        
 
EDDP ICB 2/SB 2 – ICB 1/SB 1 14 -0.33+/-0.66 27.0+/-15.4 -2.24 -0.12 0.37 0.030* 
 ICB 2/FB 2 – ICB 1/FB 1  -0.23+/-0.65  -1.33 -0.16 0.85 0.19 
 ICB 2/PB 2 – ICB 1/PB 1  -0.29+/-0.88  -2.34 -0.14 0.81 0.43 
 SB 2/FB 2 – SB 1/FB 1  0.04+/-0.60  -0.96 0.02 1.14 0.86 
 SB 2/PB 2 – SB 1/PB 1  0.07+/-0.45  -0.77 0.00 0.83 0.76 
 FB 2/PB 2 – FB 1/PB 1  -0.10+/-1.24  -2.66 -0.16 2.08 0.71 
Morphine ICB 2/SB 2 – ICB 1/SB 1 16 0.42+/-1.92 29.0+/-14.3 -2.89 0.03 6.17 0.38 
 ICB 2/FB 2 – ICB 1/FB 1  0.40+/-1.70   -1.76 0.05 4.96 0.53 
 ICB 2/PB 2 – ICB 1/PB 1  0.91+/-2.67  -3.23 0.33 8.60 0.25 
 SB 2/FB 2 – SB 1/FB 1  0.06+/-0.78  -1.41 0.03 1.24 0.74 
 SB 2/PB 2 – SB 1/PB 1  0.27+/-1.25  -2.49 0.21 3.31 0.19 
 FB 2/PB 2 – FB 1/PB 1  0.27+/-1.75  -4.21 0.14 4.90 0.83 
         
Morphine-3-G ICB 2/SB 2 – ICB 1/SB 1 15 -0.10+/-0.50 29.6+/-14.6 -1.41 -0.09 0.59 0.60 
 ICB 2/FB 2 – ICB 1/FB 1  -0.02+/-0.79  -1.89 -0.10 1.66 0.98 
 ICB 2/PB 2 – ICB 1/PB 1  0.22+/-0.64  -1.03 -0.18 1.50 0.17 
 SB 2/FB 2 – SB 1/FB 1  0.24+/-0.76  -0.94 0.05 2.02 0.39 
 SB 2/PB 2 – SB 1/PB 1  0.69+/-1.00  -0.17 0.35 3.72 0.0020* 
 FB 2/PB 2 – FB 1/PB 1  1.54+/-4.12  -0.46 0.13 16.07 0.0042* 
         
Morphine-6-G ICB 2/SB 2 – ICB 1/SB 1 12 -0.12+/-0.68 30.9+/-16.2 -1.96 0.13 0.50 0.85 
 ICB 2/FB 2 – ICB 1/FB 1  -1.65+/-4.90  -17.0 -0.25 0.61 0.23 
 ICB 2/PB 2 – ICB 1/PB 1  -0.59+/-3.39  -11.2 0.34 1.17 0.20 
 SB 2/FB 2 – SB 1/FB 1  0.36+/-2.50  -3.00 -0.04 7.59 1.00 
 SB 2/PB 2 – SB 1/PB 1  2.40+/-6.57  0.01 0.39 23.19 0.0005* 
 FB 2/PB 2 – FB 1/PB 1  2.35+/-4.46  -0.27 0.62 12.72 0.0021* 
 
 
 
 
TABLE 7—Free morphine/total morphine mean ratios differences in cases sampled twice. 
Site  Mean +/- SD Min Median Max Wilcoxon p-
value 
ICB ICB 1 0.37 +/-0.17 0.16 0.34 0.68  
 ICB 2 0.51 +/-0.19 0.18 0.52 0.80  
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 Difference 0.14 +/-0.24 -0.18 0.11 0.64 0.13 
      
 
SB SB 1  0.29 +/-0.18 0.12 0.21 0.67  
 SB 2 0.35 +/-0.20 0.13 0.29 0.81  
 Difference  0.06 +/-0.06 -0.04 0.06 0.14 0.0021* 
      
 
FB FB 1  0.22 +/-0.13 0.09 0.16 0.47  
 FB 2 0.29 +/-0.19 0.09 0.23 0.74  
 Difference  0.07 +/-0.08 -0.03 0.05 0.26 0.0021* 
      
 
PB PB 1  0.20 +/-0.13 0.08 0.14 0.46  
 PB 2 0.30 +/-0.17 0.09 0.26 0.61  
 Difference  0.11 +/-0.08 0.01 0.12 0.28 0.0005* 
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Figure Legends 
 
FIG. 1—Diazepam, nordiazepam, and oxazepam mean concentrations according to sampling sites in all cases 
(group #1). 
 
FIG. 2—Methadone and EDDP mean concentrations according to sampling sites in all cases (group #1). 
 
FIG. 3—Morphine, morphine-3-glucuronide and morphine-6-glucuronide mean concentrations according to 
sampling sites in all cases (group #1). 
 
FIG. 4—Diazepam, nordiazepam, and oxazepam mean concentrations according to sampling techniques at 
subclavian and femoral sites (a,b,c = group #2; a’,b’,c’ = group #3).   
 
FIG. 5—Methadone and EDDP mean concentrations according to sampling techniques at subclavian and 
femoral sites (a,b = group #2; a’,b’ = group #3).   
 
FIG. 6—Morphine, morphine-3-glucuronide, and morphine-6-glucuronide mean concentrations according to 
sampling techniques at subclavian and femoral sites (a,b,c = group #2; a’,b’,c’ = group #3).   
 
FIG. 7—Diazepam, nordiazepam, and oxazepam mean concentrations differences between samples 1 and 2 
according to sampling sites in cases sampled twice.  
 
FIG. 8—Methadone and EDDP mean concentrations differences between samples 1 and 2 according to 
sampling sites in cases sampled twice. 
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FIG. 9—Morphine, morphine-3-glucuronide, and morphine-6-glucuronide mean concentrations differences 
between samples 1 and 2 according to sampling sites in cases sampled twice.  
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